.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,393,203

« Back to Dashboard

Claims for Patent: 9,393,203

Title:Osmotic drug delivery system
Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Bhatt; Padmanabh P (Rockville, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:14/881,374
Patent Claims: 1. A solid dosage form comprising an oral osmotic pharmaceutical delivery composition comprising an osmotically active drug core surrounded by a semi-permeable membrane, wherein the osmotically active drug core comprises A) at least one solid release enhancing agent, which is a surfactant selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, sodium lauryl sulfate, and sodium docusate, and B) a pharmaceutically acceptable salt of treprostinil having a water solubility of at least about 30 mg/mL, and wherein the semi-permeable membrane allows for the osmotic delivery of the treprostinil from the osmotically active drug core.

2. The solid dosage form of claim 1, wherein the at least one solid release enhancing agent comprises sodium lauryl sulfate.

3. The solid dosage form of claim 1, further comprising at least one osmotic agent.

4. A method of treating pulmonary hypertension comprising administering orally to a human subject in need thereof a solid dosage form of claim 1.

5. The method of claim 4, wherein the pharmaceutically acceptable salt of treprostinil is treprostinil diethanolamine.

6. The solid dosage form of claim 1, wherein the composition is configured to provide a therapeutically effective plasma concentration of treprostinil in a human subject for a time from about 2 hours to about 8 hours after being administered orally to the human subject.

7. The solid dosage form of claim 1, wherein the at least one solid release enhancing agent comprises at least one of sodium lauryl sulfate and sodium docusate.

8. The solid dosage form of claim 1, wherein the pharmaceutically acceptable salt of treprostinil is treprostinil diethanolamine.

9. The method of claim 4, wherein the administering results in a therapeutically effective plasma concentration of treprostinil in the human subject for a time from about 2 hours to about 8 hours after said administering.

10. The method of claim 9, wherein a minimum value of the effective plasma concentration of treprostinil is from 0.1 ng/ml to 0.2 ng/ml.

11. The method of claim 9, wherein a maximum value of the effective plasma concentration of treprostinil in the subject is from 0.5 ng/ml to 2 ng/ml.

12. The method of claim 9, wherein said administering is performed twice a day or once a day.

13. The method of claim 9, wherein said administering is performed twice a day.

14. A solid dosage form comprising an oral osmotic pharmaceutical composition comprising (a) a therapeutically effective amount of a pharmaceutically acceptable salt of treprostinil having an aqueous solubility of at least 30 mg/ml and (b) at least one solid release enhancing agent, wherein the at least one solid release enhancing agent is a surfactant selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, sodium lauryl sulfate, and sodium docusate, and wherein the composition is configured to provide an effective plasma concentration of treprostinil in a human subject for a time from about 2 hours to about 8 hours after being administered orally to the human subject.

15. The solid dosage form of claim 14, wherein the at least one solid release enhancing agent comprises at least one of sodium lauryl sulfate and sodium docusate.

16. The solid dosage form of claim 14, wherein the at least one solid release enhancing agent comprises sodium lauryl sulfate.

17. The solid dosage form of claim 1, wherein the pharmaceutically acceptable salt of treprostinil is treprostinil diethanolamine.

18. A method of treating pulmonary hypertension comprising administering orally to a human subject in need thereof a solid dosage form of claim 14.

19. The method of claim 18, wherein the pharmaceutically salt of treprostinil is treprostinil diethanolamine.

20. The method of claim 18, wherein the administering results in a minimum plasma concentration of treprostinil in the subject from 0.1 ng/ml to 0.2 ng/ml.

21. The method of claim 18, wherein the administering results in a maximum plasma concentration of treprostinil in the subject from 0.5 ng/ml to 2 ng/ml.

22. The method of claim 18, wherein said administering is performed twice a day or once a day.

23. The method of claim 18, wherein said administering is performed twice a day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc